Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer

European Urology

Volumn 65, Issue 4, 2014, Pages 683-689

  Gershman, Boris ^a   Shui, Irene M ^b   Stampfer, Meir ^b,c   Platz, Elizabeth A ^d   Gann, Peter H ^e   Sesso, Howard L ^c   Dupre, Natalie ^b   Giovannucci, Edward ^b,c   Mucci, Lorelei A ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Androgens; Mortality; Prostate cancer; Sex hormones; Testosterone

Indexed keywords

ANDROGENS; MORTALITY; PROSTATE CANCER; SEX HORMONES; TESTOSTERONE;

ADULT; AGED; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 84894450317     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.01.003     Document Type: Article

References (29)

1. T. Imamoto, H. Suzuki, and M. Yano et al. The role of testosterone in the pathogenesis of prostate cancer Int J Urol 15 2008 472 480
2. Endogenous Hormones and Prostate Cancer Collaborative Group A.W. Roddam, N.E. Allen, P. Appleby, and T.J. Key Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies J Natl Cancer Inst 100 2008 170 183
3. E.A. Platz, M.F. Leitzmann, and N. Rifai et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 14 2005 1262 1269
4. M.A. Hoffman, W.C. DeWolf, and A. Morgentaler Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163 2000 824 827
5. G. Schatzl, S. Madersbacher, and T. Thurridl et al. High-grade prostate cancer is associated with low serum testosterone levels Prostate 47 2001 52 58
6. G. Isom-Batz, F.J. Bianco Jr., M.W. Kattan, J.P. Mulhall, H. Lilja, and J.A. Eastham Testosterone as a predictor of pathological stage in clinically localized prostate cancer J Urol 173 2005 1935 1937
7. J.C. Massengill, L. Sun, and J.W. Moul et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy J Urol 169 2003 1670 1675
8. C. Teloken, C.T. Da Ros, F. Caraver, F.A. Weber, A.P. Cavalheiro, and T.M. Graziottin Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer J Urol 174 2005 2178 2180
9. G.W. Chodak, N.J. Vogelzang, R.J. Caplan, M. Soloway, and J.A. Smith Independent prognostic factors in patients with metastatic (stage D2) prostate cancer JAMA 265 1991 618 621
10. T. Imamoto, H. Suzuki, and K. Akakura et al. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer Endocr J 48 2001 573 578
11. M. Ribeiro, P. Ruff, and G. Falkson Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer Am J Clin Oncol 20 1997 605 608
12. A. Salonia, A. Gallina, and A. Briganti et al. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy Cancer 117 2011 3953 3962
13. A. Salonia, F. Abdollah, and U. Capitanio et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy Clin Cancer Res 18 2012 3648 3657
14. E. Giovannucci, A. Ascherio, E.B. Rimm, M.J. Stampfer, G.A. Colditz, and W.C. Willett Intake of carotenoids and retinol in relation to risk of prostate cancer J Natl Cancer Inst 87 1995 1767 1776
15. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group N Engl J Med 321 1989 129 135
16. M.J. Stampfer, W.C. Willett, and F.E. Speizer et al. Test of the National Death Index Am J Epidemiol 119 1984 837 839
17. P.H. Gann, C.H. Hennekens, J. Ma, C. Longcope, and M.J. Stampfer Prospective study of sex hormone levels and risk of prostate cancer J Natl Cancer Inst 88 1996 1118 1126
18. S.S. Chen, K.K. Chen, A.T. Lin, Y.H. Chang, H.H. Wu, and L.S. Chang The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis BJU Int 89 2002 710 713
19. R. Prehn On the prevention and therapy of prostate cancer by androgen administration Cancer Res 59 1999 4161 4164
20. S. Yamamoto, J. Yonese, and S. Kawakami et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy Eur Urol 52 2007 696 701
21. S. Madersbacher, G. Schatzl, and C. Bieglmayer et al. Impact of radical prostatectomy and TURP on the hypothalamic-pituitary-gonadal hormone axis Urology 60 2002 869 874
22. L.R. Miller, A.W. Partin, and D.W. Chan et al. Influence of radical prostatectomy on serum hormone levels J Urol 160 1998 449 453
23. P.L. Zhang, S. Rosen, R. Veeramachaneni, J. Kao, W.C. DeWolf, and G. Bubley Association between prostate cancer and serum testosterone levels Prostate 53 2002 179 182
24. O. Lukkarinen, G.L. Hammond, M. Kontturi, and R. Vihko Peripheral and prostatic vein steroid concentrations in benign prostatic hypertrophy patients before and after removal of the adenoma Scand J Urol Nephrol 14 1980 225 227
25. A. Kjellman, O. Akre, U. Norming, M. Törnblom, and O. Gustafsson Dihydrotestosterone levels and survival in screening-detected prostate cancer: a 15-yr follow-up study Eur Urol 53 2008 106 111
26. A. Salonia, A. Briganti, and A. Gallina et al. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection Urology 73 2009 850 855
27. A. Salonia, A. Gallina, and A. Briganti et al. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy BJU Int 107 2011 1243 1249
28. J. Ma, H. Li, and E. Giovannucci et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis Lancet Oncol 9 2008 1039 1047
29. E.L. Richman, S.A. Kenfield, M.J. Stampfer, A. Paciorek, P.R. Carroll, and J.M. Chan Physical activity after diagnosis and risk of prostate cancer progression: data from the Cancer of the Prostate Strategic Urologic Research Endeavor Cancer Res 71 2011 1 7